Japan Phase III Wins, Asian Alliances Buoy Kissei's Linzagolix

US Refiling Planned

While its European licensee is preparing for an imminent launch, Kissei has also been expanding its partnerships in Asia for female health product linzagolix. A new alliance is also being sought in the US to assist with a new trial and NDA refiling there.

Kissei has expanded its licensing partnership for linzagolix while searching for a new US partner.
Kissei expands partnerships, seeking new US partner for linzagolix • Source: Shutterstock

A previous regulatory setback in the US for Kissei Pharmaceutical Co., Ltd’s female health product linzagolix has not discouraged the Japanese firm from continued development of the oral gonadotropin-releasing hormone (GnRH) antagonist and building its global presence through new alliances.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Women's Health

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By 

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.